NCT04381052View on ClinicalTrials.gov

Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions
COVID-19
Interventions
DRUG

Clazakizumab

Dose is 25mg intravenously over 30 minutes.

OTHER

Placebo

Intravenously administered over 30 minutes.

Trial Locations (1)

10032

Columbia University Medical Center / New York Presbyerian Hospital, New York

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

NYU Langone Health

OTHER

collaborator

CSL Behring

INDUSTRY

lead

Columbia University

OTHER